COMP <GO>
PHAR vs ALMS // 10Y YIELD & FRED MACRO BETA
Pharming Group N.V. ADS each representing 10 (NASDAQ) VS. Alumis Inc. (NASDAQ) • 15-METRIC TALLY: PHAR 1
— ALMS 1
■ METRIC PARITY
LAST: $12.73 (+4.09%) • MKT CAP: $863.7M
macro-sensitivity
—
LAST: $6.38 (-5.20%) • MKT CAP: $871.1M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHAR VS. ALMS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PHAR | ALMS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 69.1 | 38.2 | +30.90 | PHAR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $863.7M | $871.1M | -$7.4M | ALMS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PHAR REV | ALMS REV | PHAR GROSS % | ALMS GROSS % | PHAR FCF | ALMS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $24.1M | — | — | — | -$370.2M |
| FY 2024 | — | $842.1M | — | — | — | -$256.8M |
| FY 2023 | — | $442.9M | — | — | — | -$130.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHAR // BETA —
ALMS // BETA —